Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Fulgent Genetics ( (FLGT) ) just unveiled an update.
Fulgent Genetics reported its third quarter 2025 financial results, showing a revenue of $84.1 million, a 17% increase year-over-year, and a GAAP loss of $6.6 million. The company raised its full-year 2025 revenue guidance to $325.0 million and expects to end the year with approximately $800.0 million in cash and investments, demonstrating strong momentum in its laboratory services and therapeutic development businesses.
The most recent analyst rating on (FLGT) stock is a Hold with a $25.00 price target. To see the full list of analyst forecasts on Fulgent Genetics stock, see the FLGT Stock Forecast page.
Spark’s Take on FLGT Stock
According to Spark, TipRanks’ AI Analyst, FLGT is a Neutral.
Fulgent Genetics’ overall stock score reflects a mixed financial performance with strong technical momentum. The company’s robust revenue growth and strategic expansions are positive, but profitability and valuation remain concerns. The earnings call provided a cautiously optimistic outlook, balancing the operational challenges.
To see Spark’s full report on FLGT stock, click here.
More about Fulgent Genetics
Fulgent Genetics, Inc. is a technology-based company with a well-established laboratory services business and a therapeutic development business. The company focuses on technical laboratory and testing services, as well as developing drug candidates for cancer treatment using a novel nanoencapsulation and targeted therapy platform.
Average Trading Volume: 214,918
Technical Sentiment Signal: Hold
Current Market Cap: $697.3M
For a thorough assessment of FLGT stock, go to TipRanks’ Stock Analysis page.